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Abstract
Historically cancer vaccines have yielded suboptimal clinical results.  We have developed a novel
strategy for eliciting antitumor immunity based upon homology between neoplastic tissue and the
developing placenta. Placenta formation shares several key processes with neoplasia, namely:
angiogenesis, activation of matrix metalloproteases, and active suppression of immune function.
Immune responses against xenoantigens are well known to break self-tolerance. Utilizing
xenogeneic placental protein extracts as a vaccine, we have successfully induced anti-tumor
immunity against B16 melanoma in C57/BL6 mice, whereas control xenogeneic extracts and B16
tumor extracts where ineffective, or actually promoted tumor growth, respectively. Furthermore,
dendritic cells were able to prime tumor immunity when pulsed with the placental xenoantigens.
While vaccination-induced tumor regression was abolished in mice depleted of CD4 T cells, both
CD4 and CD8 cells were needed to adoptively transfer immunity to naïve mice. Supporting the
role of CD8 cells in controlling tumor growth are findings that only freshly isolated CD8 cells from
immunized mice were capable of inducing tumor cell caspases-3 activation ex vivo. These data
suggest feasibility of using xenogeneic placental preparations as a multivalent vaccine potently
targeting not just tumor antigens, but processes that are essential for tumor maintenance of
malignant potential.
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Introduction
For successful pregnancy to occur, establishment of hemo-
chorial placentation is essential. The process of placenta
formation involves tissue morphogenesis [1], activation
of matrix metalloproteases [2], and active suppression of
immune function [3,4]. Placental expression of matrix
metalloproteases (MMPs), [5,6], Fas ligand (Fas-L) [7]
and immune suppressants such as DAF [8], CD55 [9], IL-
10 [10], and VEGF [11] are involved in generating a suita-
ble placental microenvironment for healthy pregnancy.
The expression of the same molecules by tumor cells is
associated with poor prognosis and endows a competitive
advantage to neoplastic cells [12-16]. In addition, various
tumor antigens such as hCG, MAGE, BAGE are expressed
in placental tissue [17,18].
Induction of immune responses towards self-proteins
associated with tumor progression is a possible therapeu-
tic approach to cancer. While administration of syngeneic
or allogeneic proteins induces poor immune response, it
is reported that administration of xenogeneic homolo-
gous proteins are capable of eliciting immunity against
the endogenous self-protein. Vaccination with xenogeneic
FGF-R [19], VEGF [20], PAP [21], and MMP-2 [22]
resulted in potent immunological control of tumors that
depend on these molecules for survival. Indeed, vaccina-
tion with xenogeneic endothelial cells has been used to
block tumor angiogenesis in the recipient in an effective
manner [23-25].
Based on the above rationale, we hypothesized that
immunization with xenogeneic placental extracts would
result in a potent immune response to the inhibitory
cytokines, MMPs, and immune suppressive factors pro-
duced by the cancer. The success of this approach would
pave the way for cancer vaccines effective against a wide
variety of tumors since it does not involve targeting tissue-
specific markers, but molecules essential for the existence
and propagation of the tumor. Accordingly, in this study
we sought to demonstrate feasibility of such an approach
using the B16 murine model of melanoma, an accepted
model of immunotherapy. We have demonstrated the
ability of a single immunization to inhibit tumor growth
in a CD4+ T cell dependent manner and the need for both
CD4 and CD8 T cells to adoptively transfer immunity.
Furthermore immunization using syngeneic dendritic
cells pulsed with xenogenic placental extracts induced
immunity at the time of tumor inoculation in a semi-ther-
apeutic model. These data demonstrate feasibility of using
this novel antigenic source as a starting point for thera-
peutic vaccine development.
Materials and methods
Animals
Female C57/BL6 mice (The Jackson Laboratories, Bar Har-
bor, ME), 5 wk of age, were kept in filter-top cages at the
Animal Care and Veterinary Services Facility, the Univer-
sity of Western Ontario according to the Canadian Coun-
cil for Animal Care Guidelines. Mice were fed by food and
water ad libitum and allowed to settle for 2 wk before ini-
tiation of experimentations
Preparation of xenogeneic placental extract and controls
Porcine placental tissue was obtained from delivering
sows and washed in sterile phosphate buffered saline
(PBS) containing 5% penicillin streptomycin mixture and
placed on ice for transportation. Vascularized placental
tissue was homogenized with a tissue grinder and exposed
to 4 freeze-thaw cycles alternating from liquid nitrogen to
42 Celsius water bath. Cell debris was pelleted by centrif-
ugation at 1500 g for 45 minutes. Supernatant was col-
lected and sterilized with 0.2 micron Millipore filters.
Total protein concentration was determined using the
Bradford Assay (BioRad). For control tissue, porcine liver
and B16 melanoma cell line proteins were isolated using
identical protocol. Experiments utilizing allogeneic pla-
cental extracts were performed using term-BALB/c placen-
tal extracts prepared in a manner identical to the
xenogeneic placental extracts. The whole protein prepara-
tions were dissolved into sterile, injection-grade PBS at a
concentration of 2 mg/ml, and injections of 50 uL (total
mass 10 ug) were performed subcutaneously into C57/
BL6 mice 7 days before tumor challenge.
Pulsing of dendritic cells
At Day 0, bone marrow cells were flushed from the femurs
and tibias of C57/BL6 mice, washed and cultured in 6-
well plates (Corning, NY) at 4 × 106 cells/well in 4 ml of
complete medium (RPMI 1640 supplemented with 2 mM
L-glutamine, 100 U/ml penicillin, 100 µg of streptomy-
cin, 50 µM 2-ME, and 10% FCS (all from Life Technolo-
gies, Ontario, Canada) supplemented with recombinant
GM-CSF (10 ng/ml; PeproTech, Rocky Hill, NJ) and
recombinant mouse IL-4 (10 ng/ml; PeproTech). All cul-
tures were incubated at 37°C in 5% humidified CO2.
Non-adherent cells were removed after 48 h of culture
(Day 2) and fresh medium was added. After 7 days of cul-
ture, >90% of the cells expressed the characteristic DC-
specific marker CD11c asdetermined by FACS. DC were
washed and plated in 24-well platesat a concentration of
2 × 105 cells/well in 400 µl ofserum-free RPMI 1640. Puls-
ing with XPE and/or OVA was performed by addition of
said antigens at a concentration of 10 ug/ml for 24 hours.
Proliferation assays
Proliferative recall responses to XPE and ovalbumin in
immunized mice were assessed by sacrificing C57/BL6Journal of Translational Medicine 2006, 4:22 http://www.translational-medicine.com/content/4/1/22
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mice, 14 days after immunization with antigen-loaded
DC. T cells were purified from suspensions of lymph
nodes using CD4+ T cell column (R&D Systems) after
washing in PBS. Purified T cells were cultured in 96 well
plates with irradiated syngeneic splenocytes in triplicate
and mixed with serial dilutions of OVA at concentrations
ranging from 0–10 ug/ml. Following a 72-h incubation, 1
µCi of [3H]thymidine (Amersham) was added to each
well for 16 h. Using an automated cell harvester, the cells
were collected onto glass microfiber filter, and the radio-
active labeling incorporation was measured by a Wallac
Betaplate liquid scintillation counter.
Detection of CD8 T cell mediated caspase-3 activation
Flow cytometry was used to assess ability of CD8 cells to
mediate induction of apoptosis pathway in target cells.
Briefly, CD8 T cells were isolated from spleens of experi-
mental and control mice on day 8 after immunization
using the Murine CD8 Subset Column Kit (R&D Systems,
Minneapolis, MN) according to the manufacturer's
instructions. Cultures were prepared in RPMI 1640
medium (Invitrogen, CA) supplemented with 10% fetal
bovine serum (FBS), 100 U penicillin G, 100 µg/ml of
streptomycin sulfate and 2 mM L-glutamine. To test the
CD8 effector function in terms of caspases-3 activating
ability, the freshly isolated CD8 cells (effector cells, E)
were mixed with target tumor cells (T) labeled with Cell-
Tracker Green dye at E:T ratios equal to 50:1, 25:1, 12.5:1,
6.25:1. As targets we used B16 melanoma cells, porcine
splenocytes, murine splenocytes, as well as porcine tro-
phoblasts and murine trophoblasts isolated by enzymatic
dissociation with collagenase I and percoll density sedi-
mentation as described [26,27]. After a 3 hour co-incuba-
tion, the effector:target mixtures were washed, fixed and
permeabilized before staining with PE-labeled anti-Cas-
pase-3 antibodies (BD Pharmingen, CA). After incubation
(20 minutes, 4°C) and washing, the number of activated
caspase-3 positive apoptotic cells was detected in Cell-
Tracker Green-positive target cells population and then
the percentage of cells with activated caspases-3 were cal-
culated using CellQuest software.
ELISA
The supernatants from recall response T cell cultures were
harvested at 24 hour incubation and assessed for IFN-γ
and IL-4 by ELISA. Cytokine-specific ELISA (Endogen,
Rockford, IL) was used for detecting cytokine concentra-
tions in culture supernatants according to the manufac-
turer's instructions using a Benchmark Microplate Reader
(Bio-Rad, Hercules, CA).
B16 tumor model
For induction of tumor growth, 5 × 105 B16 American
Type Culture Collection (Manassas, VA) cells were
injected subcutaneously into the hind limb flank. Tumor
growth was assessed every 3 days by two measurements of
perpendiculardiameters by a caliper, and animals were
sacrificed when tumors reached a size of 1 cm in any direc-
tion. Tumor volume was calculated by the following for-
mula: (the shortestdiameter2 × the longest diameter)/2
Adoptive transfer
Groups of 8 mice immunized with either xenogeneic pla-
cental extract, saline, or control xenogeneic liver placental
extract were challenged on day 7 with 5 × 105 B16 cells
and observed for an additional 18 days. Subsequently,
mice were sacrificed and CD4+, and CD8+ cells were iso-
lated using the Murine CD4 Subset Column Kit, and
Murine CD8 Subset Column Kit (R&D Systems), respec-
tively. 107 CD4 and/or CD8 cells were transferred to naïve
C57/BL6 mice intravenously at time of tumor challenge
with 5 × 105 B16 cells.
Statistical analysis
Data is presented in a primarily descriptive fashion. All
experiments used 4–8 mice per treatment group and were
repeated at least 3 times. For some experiments differ-
ences in tumor size were analyzed using the two-tailed
Student's t test with significance determined at p < 0.05.
Results
Prophylaxis of tumor growth by Xenogeneic Placental 
Extract (XPE)
Induction of tumor immunity using xenogeneic antigens,
and whole cells, has been previously reported [19-25].
However these studies have utilized a variety of immuni-
zation regimens, with multiple immunizations prior to
tumor challenge. We sought to determine whether the
potency of the anti-xenogeneic response to the xenogenic
placental extract (XPE) would be sufficient to induce
tumor immunity in a single dose injection. Accordingly,
C57/BL6 mice were immunized subcutaneously with 10
µg of XPE, followed by a challenge with 5 × 105 B16
murine melanoma cells. In order to differentiate between
the non-specific immune stimulatory activity of xeno-
genic tissue injection and XPE, we used as a control a prep-
aration of xenogeneic hepatic cells prepared in a manner
identical to XPE. Although B16 cells have been previously
described as being poorly immunogenic, numerous inves-
tigators have used them for tumor vaccination [28,29], for
this reason the other control group we have used con-
sisted of B16 protein extracts purified using the method.
As seen in Figure 1, in comparison to saline treated, mice
immunized with the XPE had a significant reduction of
tumor growth. The effect of xenogenic hepatic tissue
immunization was similar to that of the saline in that
tumor growth was not significantly altered. In contrast,
growth of tumors in mice immunized with B16 extracts
was actually accelerated in comparison to the saline or
hepatic tissue extract immunized mice. Such an acceler-Journal of Translational Medicine 2006, 4:22 http://www.translational-medicine.com/content/4/1/22
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ated tumor growth may have been due to the positive
influence of certain immune responses to tumor progres-
sion as seen by others using this model [30]. Overall,
these data suggest that a single immunization with XPE is
sufficient to induce a prophylactic antitumor response.
XPE synergy with B16 vaccine
The demonstration of enhanced tumor growth in mice
immunized with B16 melanoma extracts suggested to us
that an immune response was induced, however the
response was not therapeutically desired since it actually
enhanced tumor growth. We therefore sought to deter-
mine whether XPE would be capable of modifying the
B16-induced response in order to cause inhibition of
tumor growth instead of augmentation. The rationale
being that XPE not only contains tumor antigens, but also
may be capable of triggering activation of various innate
effector cells such as dendritic cells [31]. In order to use
conditions similarly to the clinic, in this set of experi-
ments mice were immunized at the same time as tumor
inoculation. In agreement to the previously described
experiments, immunization with B16 extracts lead to an
enhancement of tumor growth, while immunization with
XPE led to inhibition (Figure 2). Interestingly, the co-
administration of B16 extracts and XPE led to a synergistic
inhibition of tumor growth (Figure 2). This ability to
potentiate immune response to B16 cells seemed to be
tumor-specific in that when EL-4 cell extracts were used
for co-immunization, no synergy of inhibition was
observed (data not shown). In summary, these experi-
ments demonstrate that XPE is not only capable of induc-
ing antitumor immunity, but also can synergize with
sources of antigen at inducing such immunity.
Dendritic cell immunization
Previous experiments have demonstrated induction of
clinically significant responses by immunizing patients
with autologous dendritic cells (DC) pulsed with xeno-
antigens [32]. Accordingly, we sought to determine
whether XPE could be used as a source of antigen for puls-
ing DC. Murine BM-derived DC were generated according
to standard protocols used by us [33], pulsed with XPE or
porcine liver extracts on day 7 for 24 hours, and injected
subcutanously on the same day as tumor challenge. DC
were confirmed to be >95% purity as detected by CD11c
expression (data not shown). Similarly to experiments
using direct immunization, XPE pulsed DC induced a
potent suppression of tumor growth, whereas DC pulsed
with control xenogenic liver extract did not evoke tumor
protection (Figure 3). In order to determine whether the
XPE augments immunity of B16 lysate "vaccine" Figure 2
XPE augments immunity of B16 lysate "vaccine". XPE 
and B16 melanoma cell lysates were prepared as described in 
Figure 1 using freeze-thaw cycles. C57/BL6 mice were immu-
nized with XPE alone or co-mixed with the B16 melanoma 
lysate diluted in PBS at a concentration of 2 mg/ml, and injec-
tions of 50 uL (total mass 10 ug). Tumor growth was 
assessed every 3 days by two measurements of perpendicular 
diameters by a caliper, and animals were sacrificed when 
tumors reached a size of 1 cm in any direction. *p < 0.05, 
Student's T test compared to saline treated.
Antitumor effects of XPE Figure 1
Antitumor effects of XPE. XPE preparations were dis-
solved into sterile, injection-grade PBS at a concentration of 
2 mg/ml, and injections of 50 uL (total mass 10 ug) were per-
formed subcutaneously into C57/BL6 mice 7 days before 
tumor challenge. 5 × 105 B16 murine melanoma cells were 
injected subcutaneously into the hind limb flank of female 6–8 
week-old C57BL/6. Tumor growth was assessed every 3 days 
by two measurements of perpendicular diameters by a cali-
per, and animals were sacrificed when tumors reached a size 
of 1 cm in any direction. *p < 0.05, Student's T test com-
pared to saline treated.Journal of Translational Medicine 2006, 4:22 http://www.translational-medicine.com/content/4/1/22
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XPE had an adjuvant effect on DC induction of immunity
similar to the synergy observed between XPE and B16
extracts in the previous experiments, we co-pulsed DC
with the antigen OVA alone, with XPE alone, or the com-
bination in non-tumor bearing C57/BL6 mice. T cell recall
responses were assayed on day 14 after immunization. As
seen in Figure 4, a stronger induction of proliferation (4a),
IFN-γ (4b) and IL-4 (4c) was observed in recall response to
OVA when DC were co-cultured with XPE before injection
as opposed to non-coculture. Overall these data suggest
that XPE can act both as a source of antigen for immune
response induction by administration through DC, and
can also act as an adjuvant to DC antigen presentation.
XPE-induced protection is CD4+ T cell dependent
Of possible mechanisms utilized by XPE to cause protec-
tion from B16 melanoma, we hypothesized that the adap-
tive immune response may be involved. Accordingly, we
depleted CD4 T cells by intravenous injection of anti-CD4
monoclonal antibody (clone GK1.5) on day -5, day -3,
day 0, day 1, day 3, and day 5 at a concentration of 150
ug/mouse. Depletion (>95% compared to control Ig
treated) was confirmed by flow cytometry (data not
shown). As seen in Figure 5, immunization with XPE did
not induce protection in the CD4 depleted mice, but
induced protection in mice having a wild-type CD4
immune response. These data suggest the importance of
adaptive immunity, as coordinated by CD4 T cells, at
mediating the cancer inhibitory activities of XPE.
XPE-induced anti-tumor response is associated with 
generation of CD8 cells capable of activating caspase-3
In order to determine whether XPE induced anti-tumor
immunity is associated with induction of cytotoxic T cells,
C57/BL6 mice were immunized with 10 µg of XPE, alloge-
neic placental extract (APE), or xenogenic liver extract and
sacrificed on day 14. CD8 T cells were extracted from
splenocytes and incubated with labeled target cells and
subsequently treated with anti-activated caspase-3 anti-
body. Assessment by flow cytometry for caspase-3 activa-
tion on target cells indicated a dose-dependent induction
of caspase 3 in B16 melanoma cells, as well as porcine tro-
phoblasts, but not in murine trophoblasts, porcine splen-
ocytes, or murine splenocytes (Figure 6). When effector
cells were isolated from mice immunized with APE or
xenogenic liver extracts, no activation of caspase-3 was
detected regardless of effector:target ratio (data not
shown). These results support the notion that CD8 T cells
are generated subsequent to XPE administration that are
capable of inducing the activation of apoptotic pathways
in target cells. The observation that neither APE immuni-
zation, nor xenogeneic liver extract immunization lead to
activation of CD8 cells with caspase-3 inducing activity
suggests a somewhat specific effect of xenogenicity on
induction of anti-tumor effects of XPE, as well as that the
effect is not mediated by non-placental tissue.
Transfer of XPE-induced protection requires CD4 and CD8 
T cells
To conclusively demonstrate that the induction of lym-
phoid effector cells subsequent to XPE vaccination is caus-
ative of tumor regression, we performed a standard
adoptive transfer experiment. Groups of 8 mice were
immunized with XPE or xenogeneic liver extracts as
described in Figure 1, challenged with tumors on day 7,
and subsequently sacrificed 18 days subsequent to tumor
challenge. CD4 and CD8 cells were isolated and trans-
ferred into naïve C57/BL6 mice at the time of tumor chal-
lenge. As seen in Figure 7, only the co-transfer of both
CD4+ and CD8+ cells was capable of inducing tumor
inhibition. Adoptive transfer of immune cells from mice
immunized with xenogenic liver extracts had no inhibi-
tory effect (data not shown).
Discussion
It has been reported that immunization with placental
extracts possesses clinical efficacy toward a variety of
tumor types clinically, as previously reviewed by Harandi
[34]. Unfortunately, randomized clinical trials have not
been performed and the data is at best anecdotal. Concep-
tually, vaccination with placental extracts would be capa-
ble of eliciting immunological responses not only to
marker antigens shared between the placenta and neopla-
sia such as hCG, MAGE, BAGE [17,18], but also to func-
tional proteins that tumors require to maintain
Induction of anti-cancer immunity by XPE-pulsed DC Figure 3
Induction of anti-cancer immunity by XPE-pulsed 
DC. Day 7 bone marrow-derived DC were pulsed with 10 
µg/ml XPE for 24 h and injected s.c. (5 × 105 cells/mouse) 
into syngeneic C57BL/6 mice. A concurrent injection of 5 × 
105 B16 melanoma cells was administered. Tumor growth 
was assessed every 3 days by two measurements of perpen-
dicular diameters by a caliper, and animals were sacrificed 
when tumors reached a size of 1 cm in any direction. *p < 
0.05, Student's T test compared to saline treated.Journal of Translational Medicine 2006, 4:22 http://www.translational-medicine.com/content/4/1/22
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malignancy. For example, stimulation of immunity
against MMPs found on placental tissue may theoretically
cause inhibition of tumor MMP activity and reduction in
tissue invasiveness and metastasis. Indeed, while others
have previously demonstrated inhibition of tumor growth
after immunization with MMP-2 [22], it was recently
observed that human melanoma cells uptake MMP-2 in
an alpha v beta3-dependent manner, and present peptides
thereof to HLA*0201-restricted T cells [35].
In addition to MMPs, placental formation in normal preg-
nancy is dependent on two other main functional activi-
ties, the first being suppression of immune responses in a
selective or semi-selective manner, and the second being
ability to rapidly induce angiogenesis to form the appro-
priate interface for maternal-fetal nutrient transmission. It
is established that tumors also require induction of
immune suppression, as well as angiogenesis for their sur-
vival, and indeed the higher immune suppression and
angiogenesis found in tumors, the worse the patient prog-
nosis is. The sharing between placental cells and cancer
cells of immune suppression/immune evasion molecules
such as fas ligand (Fas-L) [7], DAF [8], CD55 [9], IL-10
[10], MICA [36], HLA-G and indolamine 2,3 dioxygenase
[37], as well as molecules of angiogenesis such as VEGF
[11], placental growth factor [38], angiopoietin [39], FGF,
EGF, and TGF-beta [40] suggests not only a functional,
but also a molecular homology between placenta and
cancer cells.
The knowledge that placental extracts may be stimulatory
of anticancer immune responses has been postulated to
account for the lower incidence of certain tumors in
multi-parous women [41]. Indeed older studies using pla-
cental immunization in mouse models have demon-
strated some efficacy in tumor inhibition as reviewed by
Harandi [34]. Our approach to utilization of placental
extracts was mindful of the Immunostimulatory Hypoth-
esis proposed by Prehn [42], suggesting that the immune
response may in some cases actually contribute to tumor
growth. With this in mind, we sought to specifically use a
potent means of inducing a "danger signal" while concur-
rently providing a multivalent tumor antigenic source.
Based on the hyperacute nature of xenogenic rejection
[43], the multitude of data supporting superior breaking
of tolerance using xenogenic variants of self-proteins [44-
46], and the fact that autoimmune disease is evoked only
by xenogeneic self antigens in animal models of autoim-
mune disease [47,48], we decided to immunize C57/BL6
mice with xenogenic placental extracts (XPE) and observe
antitumor effects.
We have demonstrated that immunization with a prepa-
ration of xenogenic placental extract induced a CD4-
Potentiation of immunity by XPE pulsed DC Figure 4
Potentiation of immunity by XPE pulsed DC. C57/BL6 mice were injected were injected subcutaneously with 5 × 105 
bone marrow-derived DC pulsed with either 10 µg/ml XPE, and/or 10 µg/ml OVA for 24 hr. Mice were sacrificed 14 days post 
inoculation and splenocytes were cultured with increasing concentrations of OVA in vitro. Cultures were assessed for: A) Pro-
liferation; B) IFN-γ production; and C) IL-4 production.Journal of Translational Medicine 2006, 4:22 http://www.translational-medicine.com/content/4/1/22
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dependent immune response capable of inhibiting
growth of B16 melanoma cells in the C57/BL6 mouse.
Demonstration of CD8 activity in the induction of tumor
regression was performed in experiments showing that
freshly isolated CD8 cells from immunized mice were
capable of inducing both tumor cell, as well as xenogeneic
trophoblast apoptosis cascades. Immune-mediated clear-
ance seemed to be specific to the XPE since immunization
with control porcine liver extracts did not mediate protec-
tion. Additionally, the xenogeneic component of XPE
seems to be critical since apoptosis-inducing cells were
not detected in mice immunized with allogeneic placental
extracts. Although we did not elucidate specific antigenic
targets of xenoplacental immunization, preliminary data
seems to suggest that inhibition of neoangiogenesis may
be one of the potent mechanisms. Studies using purified
immunoglobulin from XPE immunized mice demon-
strate the ability to inhibit in vitro proliferation of
endothelial cells. This work is still in progress and will be
reported in a subsequent publication.
The ability of XPE to inhibit tumor growth may not be sur-
prising given the high concentration of endothelial cells
in placental tissue, and previous reports that immuniza-
tion with xeno-endothelial cells causes anticancer
responses [25,49]. However, the potent ability of XPE to
act as a Th1 and Th2 adjuvant for HEL-specific recall
responses is surprising. Indeed it has been speculated that
xenogenic antigens may intrinsically be stimulatory of
dendritic cell function, however to our knowledge, this is
the first report actually demonstrating this. Future experi-
ments will assess the effect of XPE on dendritic cell matu-
ration, and function in vitro in order to identify whether
the XPE was actually giving a direct signal to dendritic
cells, or whether the augmentation of DC activation
occurs after the re-introduction of pulsed DC in vivo. Nev-
ertheless, it appears that XPE has a potent immune
enhancing property since it was able to potentiate the
Adoptive transfer of XPE-induced immunity Figure 7
Adoptive transfer of XPE-induced immunity. Mice 
were immunized with XPE, challenged on day 7 with 5 × 105 
B16 cells, observed for an additional 18 days after which 
CD4+, and CD8+ cells were harvested from splenocytes. 
CD4 and CD8 cells were transferred alone or together at a 
concentration of 107 cells/mouse to naïve C57/BL6 mice 
intravenously at time of tumor challenge with 5 × 105 B16 
cells.
XPE-induced anti-tumor immunity is CD4 dependent Figure 5
XPE-induced anti-tumor immunity is CD4 depend-
ent. CD4 cell depletion was accomplished in C57/BL6 mice 
by intravenous injection of anti-CD4 monoclonal antibody 
(clone GK1.5) on day -5, day -3, day 0, day 1, day 3, and day 5 
at a concentration of 150 ug/mouse. XPE was injected on day 
0, which was also the timepoint of tumor injection (5 × 105 
B16) Tumor growth was assessed every 3 days by two meas-
urements of perpendicular diameters by a caliper, and ani-
mals were sacrificed when tumors reached a size of 1 cm in 
any direction. *p < 0.05, Student's T test compared to saline 
treated.
XPE-induction of caspase-3 activating CD8 cells Figure 6
XPE-induction of caspase-3 activating CD8 cells. CD8 
T cells were isolated from spleens of experimental and con-
trol mice on day 8 after immunization with XPE and mixed at 
the indicated ratios with the indicated target cells. Caspase-3 
activation was quantified as percentage of target cells positive 
for anti-activated caspase-3 antibody staining by flow cytome-
try. The results are representative of 3 independently per-
formed experiments.Journal of Translational Medicine 2006, 4:22 http://www.translational-medicine.com/content/4/1/22
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anti-B16 response of the B16 lysate vaccine in addition to
the anti-HEL response.
Although numerous tumor antigens are currently under
intense investigation, the ability for a multi-epitopic com-
position such as XPE to induce immunity that is transfer-
able to naïve recipients is somewhat surprising given the
lack of immunological adjuvants or multi-injection regi-
mens used in other studies. In conclusion, XPE appears to
be a potent stimulator of anticancer immune responses in
a CD4 and CD8 T cell dependent manner. The characteri-
zation of both cross-reactive tumor antigens, as well as the
apparent ability to act as an immunological adjuvant, will
provide interesting new avenues of research, with the pos-
sibility of developing novel, clinically applicable thera-
peutics from a relatively benign antigenic source.
Acknowledgements
The authors express many thanks to Carmen Molinaro for unwavering sup-
port and contributions that were essential to success of this study. We also 
thank Guillermo Arreaza from the NIH for critical reviews and comments.
References
1. Regnault TR, Galan HL, Parker TA, Anthony RV: Placental devel-
opment in normal and compromised pregnancies-- a review.
Placenta 2002, 23 Suppl A:S119-29.
2. Curry TEJ, Osteen KG: The matrix metalloproteinase system:
changes, regulation, and impact throughout the ovarian and
uterine reproductive cycle.  Endocr Rev 2003, 24:428-465.
3. Szekeres-Bartho J: Immunological relationship between the
mother and the fetus.  Int Rev Immunol 2002, 21:471-495.
4. Pijnenborg R: Implantation and immunology: maternal inflam-
matory and immune cellular responses to implantation and
trophoblast invasion.  Reprod Biomed Online 2002, 4 Suppl
3:14-17.
5. Bischof P, Meisser A, Campana A: Control of MMP-9 expression
at the maternal-fetal interface.  J Reprod Immunol 2002, 55:3-10.
6. Xu P, Alfaidy N, Challis JR: Expression of matrix metalloprotei-
nase (MMP)-2 and MMP-9 in human placenta and fetal mem-
branes in relation to preterm and term labor.  J Clin Endocrinol
Metab 2002, 87:1353-1361.
7. Aschkenazi S, Straszewski S, Verwer KM, Foellmer H, Rutherford T,
Mor G: Differential regulation and function of the Fas/Fas lig-
and system in human trophoblast cells.  Biol Reprod 2002,
66:1853-1861.
8. Cunningham DS, Tichenor JRJ: Decay-accelerating factor pro-
tects human trophoblast from complement-mediated
attack.  Clin Immunol Immunopathol 1995, 74:156-161.
9. Holmes CH, Simpson KL: Complement and pregnancy: new
insights into the immunobiology of the fetomaternal rela-
tionship.  Baillieres Clin Obstet Gynaecol 1992, 6:439-460.
10. Rein DT, Breidenbach M, Honscheid B, Friebe-Hoffmann U, Engel H,
Gohring UJ, Uekermann L, Kurbacher CM, Schondorf T: Preec-
lamptic women are deficient of interleukin-10 as assessed by
cytokine release of trophoblast cells in vitro.  Cytokine 2003,
23:119-125.
11. Zygmunt M, Herr F, Munstedt K, Lang U, Liang OD: Angiogenesis
and vasculogenesis in pregnancy.  Eur J Obstet Gynecol Reprod Biol
2003, 110 Suppl:S10-8.
12. Bischof P, Campana A: A putative role for oncogenes in tro-
phoblast invasion?  Hum Reprod 2000, 15 Suppl 6:51-58.
13. Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D,
O'Dwyer ST, Jayson GC: Vascular endothelial growth factors C
and D and lymphangiogenesis in gastrointestinal tract malig-
nancy.  Br J Cancer 2003, 89:426-430.
14. Kurzrock R: Cytokine deregulation in cancer.  Biomed Pharmaco-
ther 2001, 55:543-547.
15. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L,
Imperatore V, Catalano G, Pignatelli C, De Vita F: Prognostic sig-
nificance of circulating IL-10 and IL-6 serum levels in colon
cancer patients undergoing surgery.  Clin Immunol 2002,
102:169-178.
16. Nozoe T, Yasuda M, Honda M, Inutsuka S, Korenaga D: Fas ligand
expression is correlated with metastasis in colorectal carci-
noma.  Oncology 2003, 65:83-88.
17. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT: Cancer/testis
antigens: an expanding family of targets for cancer immuno-
therapy.  Immunol Rev 2002, 188:22-32.
18. Zendman AJ, Van Kraats AA, Weidle UH, Ruiter DJ, Van Muijen GN:
The XAGE family of cancer/testis-associated genes: align-
ment and expression profile in normal tissues, melanoma
lesions and Ewing's sarcoma.  Int J Cancer 2002, 99:361-369.
19. He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L, Lu Y, Kan B, Lou YY,
Huang MJ, Xiao F, Liu JY, Hu B, Luo F, Jiang Y, Wen YJ, Deng HX, Li
J, Niu T, Yang JL: Inhibition of tumor growth with a vaccine
based on xenogeneic homologous fibroblast growth factor
receptor-1 in mice.  J Biol Chem 2003, 278:21831-21836.
20. Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y, Shu JM, Lu CJ, Niu
T, Kang B, Mao YQ, Liu F, Wen YJ, Lei S, Luo F, Zhou LQ, Peng F,
Jiang Y, Liu JY, Zhou H, Wang QR, He QM, Xiao F, Lou YY, Xie XJ,
Li Q, Wu Y, Ding ZY, Hu B, Hu M, Zhang W: Immunogene ther-
apy of tumors with vaccine based on Xenopus homologous
vascular endothelial growth factor as a model antigen.  Proc
Natl Acad Sci U S A 2001, 98:11545-11550.
21. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R: Induction of
tissue-specific autoimmune prostatitis with prostatic acid
phosphatase immunization: implications for immuno-
therapy of prostate cancer.  J Immunol 1997, 159:3113-3117.
22. Su JM, Wei YQ, Tian L, Zhao X, Yang L, He QM, Wang Y, Lu Y, Wu
Y, Liu F, Liu JY, Yang JL, Lou YY, Hu B, Niu T, Wen YJ, Xiao F, Deng
HX, Li J, Kan B: Active immunogene therapy of cancer with
vaccine on the basis of chicken homologous matrix metallo-
proteinase-2.  Cancer Res 2003, 63:600-607.
23. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ,
Huang MJ, Lou YY, Xiao F, He QM, Shu JM, Xie XJ, Mao YQ, Lei S,
Luo F, Zhou LQ, Liu CE, Zhou H, Jiang Y, Peng F, Yuan LP, Li Q, Wu
Y, Liu JY: Immunotherapy of tumors with xenogeneic
endothelial cells as a vaccine.  Nat Med 2000, 6:1160-1166.
24. Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, Yazawa
K, Asakage M, Hori N, Watanabe T, Shibata Y, Takahashi K, Nagawa
H: Vaccination with autologous endothelium inhibits angio-
genesis and metastasis of colon cancer through autoimmu-
nity.  Cancer Sci 2004, 95:85-90.
25. Scappaticci FA, Contreras A, Boswell CA, Lewis JS, Nolan G: Poly-
clonal antibodies to xenogeneic endothelial cells induce
apoptosis and block support of tumor growth in mice.  Vaccine
2003, 21:2667-2677.
26. Yu Z, Croy BA, King GJ: Lysis of porcine trophoblast cells by
endometrial natural killer-like effector cells in vitro does not
require interleukin-2.  Biol Reprod 1994, 51:1279-1284.
27. Zuckermann FA, Head JR: Isolation and characterization of tro-
phoblast from murine placenta.  Placenta 1986, 7:349-364.
28. Stackpole CW, Alterman AL, Braverman S, Rappaport I: Develop-
ment of host immunity to phenotypically diverse B16
melanoma clones. Implications for tumor growth and
metastasis.  Invasion Metastasis 1987, 7:346-366.
29. Terao H, Harada M, Kurosawa S, Shinomiya Y, Okamoto T, Ito O,
Sumichika H, Takenoyama M, Nomoto K: Th1 type CD4+ T cells
may be a potent effector against poorly immunogenic syn-
geneic tumors.  Biotherapy 1994, 8:143-151.
30. Ershler WB, Tuck D, Moore AL, Klopp RG, Kramer KE: Immuno-
logic enhancement of B16 melanoma growth.  Cancer 1988,
61:1792-1797.
31. Manna PP, Steward N, Lowell J, Mohanakumar T: Differentiation
and functional maturation of human CD14(+) adherent
peripheral blood monocytes by xenogeneic endothelial cells:
up-regulation of costimulation, cytokine generation, and
toll-like receptors.  Transplantation 2002, 74:243-252.
32. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Eng-
leman EG: Dendritic cell-based xenoantigen vaccination for
prostate cancer immunotherapy.  J Immunol 2001,
167:7150-7156.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Translational Medicine 2006, 4:22 http://www.translational-medicine.com/content/4/1/22
Page 9 of 9
(page number not for citation purposes)
33. Ichim TE, Popov IA, Riordan NH, Izadi H, Zhong Z, Yijian L, Sher S,
Oleinik EK: A novel method of modifying immune responses
by vaccination with lipiodol-siRNA mixtures.  J Transl Med
2006, 4:2.
34. Harandi A: Immunoplacental therapy, a potential multi-
epitope cancer vaccine.  Med Hypotheses 2006.
35. Godefroy E, Moreau-Aubry A, Diez E, Dreno B, Jotereau F, Guilloux
Y:  alpha v beta3-dependent cross-presentation of matrix
metalloproteinase-2 by melanoma cells gives rise to a new
tumor antigen.  J Exp Med 2005, 202:61-72.
36. Mincheva-Nilsson L, Nagaeva O, Chen T, Stendahl U, Antsiferova J,
Mogren I, Hernestal J, Baranov V: Placenta-Derived Soluble MHC
Class I Chain-Related Molecules Down-Regulate NKG2D
Receptor on Peripheral Blood Mononuclear Cells during
Human Pregnancy: A Possible Novel Immune Escape Mech-
anism for Fetal Survival.  J Immunol 2006, 176:3585-3592.
37. Honig A, Rieger L, Kapp M, Sutterlin M, Dietl J, Kammerer U:
Indoleamine 2,3-dioxygenase (IDO) expression in invasive
extravillous trophoblast supports role of the enzyme for
materno-fetal tolerance.  J Reprod Immunol 2004, 61:79-86.
38. Parr C, Watkins G, Boulton M, Cai J, Jiang WG: Placenta growth
factor is over-expressed and has prognostic value in human
breast cancer.  Eur J Cancer 2005, 41:2819-2827.
39. Birk RZ, Burstein E, Wiznitzer A: Placental angiopoietin-1 and
angiopoietin-2 expression and correlation with birth weight
in twins.  J Matern Fetal Neonatal Med 2005, 17:337-342.
40. Marzioni D, Capparuccia L, Todros T, Giovannelli A, Castellucci M:
Growth factors and their receptors: fundamental molecules
for human placental development.  Ital J Anat Embryol 2005,
110:183-187.
41. Botelho F, Clark DA: How might pregnancy immunize against
breast cancer?  Am J Reprod Immunol 1998, 39:279-283.
42. Prehn RT: Stimulatory effects of immune reactions upon the
growths of untransplanted tumors.  Cancer Res 1994,
54:908-914.
43. Schuurman HJ, Cheng J, Lam T: Pathology of xenograft rejection:
a commentary.  Xenotransplantation 2003, 10:293-299.
44. Ciesielski MJ, Apfel L, Barone TA, Castro CA, Weiss TC, Fenster-
maker RA: Antitumor effects of a xenogeneic survivin bone
marrow derived dendritic cell vaccine against murine GL261
gliomas.  Cancer Immunol Immunother 2006.
45. Mincheff M, Zoubak S, Makogonenko Y: Immune responses
against PSMA after gene-based vaccination for immuno-
therapy - A: results from immunizations in animals.  Cancer
Gene Ther 2005.
46. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM,
Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P,
Houghton AN, Perales MA, Wolchok JD: Development of a xeno-
geneic DNA vaccine program for canine malignant
melanoma at the Animal Medical Center.  Vaccine 2005.
47. Blass S, Engel JM, Burmester GR: [The immunologic homunculus
in rheumatoid arthritis. A new viewpoint of immunopatho-
genesis in rheumatoid arthritis and therapeutic conse-
quences].  Z Rheumatol 2001, 60:1-16.
48. Sgroi D, Cohen RN, Lingenheld EG, Strong MK, Binder T, Goldsch-
neider I, Greiner D, Grunnet M, Clark RB: T cell lines derived
from the spinal cords of mice with experimental allergic
encephalomyelitis are self reactive.  J Immunol 1986,
137:1850-1854.
49. Ichim CV: Revisiting immunosurveillance and immunostimu-
lation: Implications for cancer immunotherapy.  J Transl Med
2005, 3:8.